Comparative study on cefprozil and cefaclor in the treatment of respiratory tract infections

胡必杰,何礼贤,金美玲,洪群英
DOI: https://doi.org/10.3969/j.issn.1001-8689.2003.02.012
2003-01-01
Abstract:Objective: To study the efficacy and safety of cefprozil in tereatment of community acquired respiratory tract infections (CARTI). Method: An open, comparative, multicenter clinical trial was performed in 9 hospitals in Beijing, Shanghai, Wuhan and Dalian from April 2000 to September 2000. The clinical and bacteriological efficacy and safety were compared between cefprozil and cefaclor in treating mild to moderate CARTI. Results: A total of 417 patiens was enrolled: upper respiratory tract infections (URTI) 227, lower respiratory tract infections (LRTI) 190. Among them, 222 patients were assigned to cefprozil group while 195 patients to cefaclor group. Sex, age, fever, WBC and PMN, bacteria spectrum were similar between groups (P > 0.05). The regimens were as follows: cefrozil 500mg qd for URTI or 500mg bid for LRTI, cefaclor 250mg tid for URTL or 500mg tid for LRTI. The duration was 7 - 14d for all patients. The clinical efficacy of cefprozil, in URTI and LRTI was 94.7% and 92.2%, higher than that of cefaclor (91.5% and 83.0%). Successful bacteriological eradication of the causative pathogen in both URTI and LRTI was 90.8% in cefprozil and 85.5% in cefaclor. However, statistic analysis did not show significant differences (P > 0.05). Sensitivity testing showed that Streptococcus pneumoniae, beta-hemolytic Streptococci, Haemophilus influenzae and Parainfluenzae, Staphylococcus aureus and Klebsiella pneumoniae isolated in these CARTI were sensitive to cefprozil and cefaclor with the rate 90.9 % - 100.0% and 91.9% - 100.0% respectively. Side effects in both groups were low with 5.9% for cefprozil and 4.6% for cefaclor (P > 0.05). Liver and kidney function tests in following up patients showed normal in both cefprozil and cefaclor groups (292 and 295 patients respective) at the end of treatment. Conclusion: Due to its good antibacteria activity and clinical efficacy, high bacteriological eradication and low side effect rates, cefprozil should become first line antimicrobial agent in treating mild to moderate CARTI.
What problem does this paper attempt to address?